[go: up one dir, main page]

AU1722300A - Chlamydia pneumoniae genome sequence - Google Patents

Chlamydia pneumoniae genome sequence

Info

Publication number
AU1722300A
AU1722300A AU17223/00A AU1722300A AU1722300A AU 1722300 A AU1722300 A AU 1722300A AU 17223/00 A AU17223/00 A AU 17223/00A AU 1722300 A AU1722300 A AU 1722300A AU 1722300 A AU1722300 A AU 1722300A
Authority
AU
Australia
Prior art keywords
genome sequence
chlamydia pneumoniae
pneumoniae genome
chlamydia
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17223/00A
Inventor
Ronald Davis
Sue Kalman
Wayne Mitchell
Richard Stephens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU1722300A publication Critical patent/AU1722300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU17223/00A 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence Abandoned AU1722300A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10827998P 1998-11-12 1998-11-12
US60108279 1998-11-12
US12860699P 1999-04-08 1999-04-08
US60128606 1999-04-08
PCT/US1999/026923 WO2000027994A2 (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence

Publications (1)

Publication Number Publication Date
AU1722300A true AU1722300A (en) 2000-05-29

Family

ID=26805735

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17223/00A Abandoned AU1722300A (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence

Country Status (5)

Country Link
EP (1) EP1133572A4 (en)
JP (1) JP2002529069A (en)
AU (1) AU1722300A (en)
CA (1) CA2350775A1 (en)
WO (1) WO2000027994A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT909323E (en) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic Helicobacter pylori bacterioferritin
EP1105490A1 (en) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
CA2340283A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding pomp91a protein of chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2353107A1 (en) 1998-12-01 2000-06-08 Andrew D. Murdin Chlamydia antigens and corresponding dna fragments and uses thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
EP2277893A3 (en) 1998-12-08 2011-03-30 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2354431A1 (en) 1998-12-23 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000039157A1 (en) 1998-12-28 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
MXPA01009256A (en) 1999-03-12 2003-07-14 Aventis Pasteur Chlamydia.
EP1165828A4 (en) * 1999-03-26 2002-09-25 Human Genome Sciences Inc 50 human secreted proteins
JP2002539815A (en) * 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 47 human secreted proteins
AU780444B2 (en) 1999-05-03 2005-03-24 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2407114A1 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
NZ594877A (en) 2000-10-27 2012-07-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003278166B2 (en) 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ES2328697T5 (en) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide
JP2008504292A (en) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Immune enhancement compounds
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
SG164344A1 (en) 2005-02-18 2010-09-29 Novartis Vaccines & Diagnostics Srl Immunogens from uropathogenic escherichia coli
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2197485B1 (en) 2007-09-12 2015-11-11 GlaxoSmithKline Biologicals SA Gas57 mutant antigens and gas57 antibodies
PL2235046T3 (en) 2007-12-21 2012-12-31 Novartis Ag Mutant forms of streptolysin o
SI2349520T1 (en) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Purification method for carbohydrate from group a streptococcus
EP2379106A4 (en) * 2008-12-17 2012-06-13 Genocea Biosciences Inc Chlamydia antigens and uses thereof
BRPI1005670A8 (en) 2009-01-05 2017-12-26 Epitogenesis Inc adjuvant compositions and processes of use.
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
ES2733084T3 (en) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Chlamydia antigens
MX373250B (en) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star CONJUGATION OF TYPE 5 AND TYPE 8 CAPSULAR POLYSACCHARIDES OF STAPHYLOCOCCUS AUREUS.
BR112012010223A2 (en) 2009-10-30 2016-12-06 Novartis Ag purification of staphylococcus aureus type 5 and type 8 capsular saccharides
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012054755A1 (en) * 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
JP6499446B2 (en) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド Pharmaceutical composition containing a combination of a selective carrier, vitamin, tannin and flavonoid as an antigen-specific immune modulator
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
MX354924B (en) 2011-11-07 2018-03-22 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen.
WO2013174832A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
CN108514870B (en) * 2018-04-27 2020-02-28 湖南大学 Hydrotalcite-polym-phenylenediamine composite material and its preparation method and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374718A (en) * 1992-08-26 1994-12-20 Gen-Probe Incorporated Nucleic acid probes to chlamydia pneumoniae
JPH08294400A (en) * 1995-04-28 1996-11-12 Hitachi Chem Co Ltd Probe and primer for detecting and measuring chlamydia pneumoniae gene, detection and measurement of chlamydia pneumoniae gene using the same probe or primer and reagent for detecting and measuring chlamydia pneumoniae gene containing the same probe or primer
JPH10210978A (en) * 1997-01-31 1998-08-11 Hitachi Chem Co Ltd Recombinant vector and transformant containing the same, and recombinant vacurovirus and its production, and production of chlamydia pneumoniae antigen polypeptide

Also Published As

Publication number Publication date
JP2002529069A (en) 2002-09-10
CA2350775A1 (en) 2000-05-18
EP1133572A4 (en) 2005-06-15
WO2000027994A2 (en) 2000-05-18
EP1133572A2 (en) 2001-09-19
WO2000027994A3 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
AU1722300A (en) Chlamydia pneumoniae genome sequence
AU5793798A (en) Streptococcus pneumoniae dna sequences
AU9277698A (en) 9-amino-3-keto erythromycin derivatives
AU4962499A (en) Solid state microanemometer
AU4289399A (en) Nucleic acid transfer phage
AU5044299A (en) Multipurpose support
AU6266399A (en) Tip-plate thermocouple
AUPP210698A0 (en) Fin
AU6417799A (en) Matrix-remodeling genes
AU2001235616A1 (en) Immunostimulatory oligonucleotides
AU6932098A (en) Erythromycin derivatives
AU743869C (en) Lehr loader pusher bar assembly
AU1504899A (en) Erythromycin derivatives
AU1161500A (en) Macrolide intermediates
AU1775500A (en) Circuit-breaker
AU6217199A (en) Compositions
AUPP247498A0 (en) Improved palletizer
AUPP786998A0 (en) Hand implement
AU4513599A (en) Nucleotide sequence
AU5314999A (en) Modified oligonucleotides
AU1396100A (en) Oligonucleotide conjugation
AU3421799A (en) Microcalorimeter
AU2001235617A1 (en) Immunostimulatory oligonucleotides
AUPP728898A0 (en) Immunostimulatory dna
AU5752299A (en) Chemical compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase